Advances in the application of immune checkpoint inhibitors in gynecological tumors.

[1]  F. Fiore,et al.  Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer , 2022, Frontiers in Immunology.

[2]  Q. Cheng,et al.  Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts , 2022, Journal of Hematology & Oncology.

[3]  A. Rizzo.  Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities , 2022, Journal of clinical medicine.

[4]  G. Schwartz,et al.  Novel Therapeutics in the Treatment of Uterine Sarcoma. , 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[5]  E. Maiello,et al.  Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives , 2021, Cancers.

[6]  B. Monk,et al.  Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. , 2021, The Lancet. Oncology.

[7]  M. Stockler,et al.  Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial , 2021, Journal for ImmunoTherapy of Cancer.

[8]  K. Robison,et al.  Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Song Liu,et al.  Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. , 2020, JAMA oncology.

[10]  A. Oza,et al.  DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment , 2020, International Journal of Gynecological Cancer.

[11]  W. Lee,et al.  Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity , 2020, Experimental & Molecular Medicine.

[12]  P. Secchiero,et al.  Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile , 2020, Cancers.

[13]  A. Perrone,et al.  Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis , 2020, Cancers.

[14]  H. Matsubara,et al.  Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer , 2020, Oncology letters.

[15]  Joon-Oh Park,et al.  A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[16]  R. Burger,et al.  Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Baba,et al.  Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions , 2020, International journal of molecular sciences.

[18]  E. Schmidt,et al.  Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Green,et al.  A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[20]  K. Ushijima,et al.  Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100 , 2020, Cancer science.

[21]  Ipilimumab , 2020, Reactions Weekly.

[22]  S. M. Toor,et al.  Immune checkpoints in the tumor microenvironment. , 2020, Seminars in cancer biology.

[23]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Shih,et al.  Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer , 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[25]  Cesar M. Castro,et al.  Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. , 2019, JAMA oncology.

[26]  J. Machiels,et al.  Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Tamura,et al.  Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial , 2019, Cancer science.

[28]  Xu Li,et al.  Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout , 2019, Cancer Gene Therapy.

[29]  Yumeng Wang,et al.  PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives , 2019, Frontiers of Medicine.

[30]  E. Swisher,et al.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.

[31]  U. Matulonis,et al.  Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? , 2019, Gynecologic oncology.

[32]  D. Provencher,et al.  Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[34]  E. Schmidt,et al.  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[35]  Y. Liu,et al.  Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers , 2018, Current Oncology Reports.

[36]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[37]  K. Hargadon,et al.  Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. , 2018, International immunopharmacology.

[38]  S. Demaria,et al.  Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. , 2018, Trends in immunology.

[39]  Huyi Liang,et al.  PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer , 2018, Journal of Cancer.

[40]  J. Prat,et al.  Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. , 2018, Human pathology.

[41]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[42]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[43]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[44]  A. Dicker,et al.  Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer , 2018, Clinical Cancer Research.

[45]  W. Ji,et al.  The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance , 2018, Cancer management and research.

[46]  M. Kool,et al.  Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma , 2017, Oncoimmunology.

[47]  H. Rugo,et al.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  F. Hodi,et al.  Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study , 2017, Cancer.

[49]  S. Pignata,et al.  Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. , 2017, Cancer treatment reviews.

[50]  Giorgio Valabrega,et al.  Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity , 2017, Oncotarget.

[51]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[52]  Nan Zhang,et al.  PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer , 2017, International Journal of Clinical Oncology.

[53]  Opal L. Reddy,et al.  Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas , 2017, Diagnostic Pathology.

[54]  H. Rugo,et al.  Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Wolchok,et al.  Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies , 2017, Nature Reviews Endocrinology.

[56]  M. Köbel,et al.  Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer , 2017, Modern Pathology.

[57]  Lin Zhao,et al.  Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity , 2016, Molecular medicine reports.

[58]  M. Atkins,et al.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.

[59]  R. Lifton,et al.  Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab , 2016, Clinical Cancer Research.

[60]  Matthieu Texier,et al.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.

[61]  Gennaro Ciliberto,et al.  Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? , 2016, Cancer treatment reviews.

[62]  B. Neyns,et al.  Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. , 2016, American journal of cancer research.

[63]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[64]  G. Nuovo,et al.  Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers , 2015, Modern Pathology.

[65]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[67]  B. Weigelt,et al.  Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.

[68]  J. Wolchok,et al.  Immune Checkpoint Blockade , 2019, Methods in Molecular Biology.

[69]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[70]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[71]  Yun Feng,et al.  Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. , 2012, Immunobiology.

[72]  S. Chouaib,et al.  Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape , 2012, Front. Immun..

[73]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[74]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[75]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[76]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[77]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[78]  Y. Niibe,et al.  Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma--a case report. , 2007, Anticancer research.

[79]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[81]  A. Sharpe,et al.  CTLA-4 regulates induction of anergy in vivo. , 2001, Immunity.

[82]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[83]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[84]  Mole Rh.  Whole body irradiation; radiobiology or medicine? , 1953 .